Experience Exactech. A Great Day in the O.R.
Corporate Home Page
About Us
Exactech, Inc. is an orthopaedic company that develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Founded in 1985 by an orthopaedic surgeon and a biomedical engineer, Exactech is committed to making every day A Great Day in the O.R. For the surgeon, the operating room staff and above all, for the patient. It's the driving force behind everything we do. From innovative products and instrumentation, to training and education, to our supreme commitment to service.
Recent News
Exactech Announces Sale of Common Stock Resulting in $20.2 Million in Gross Proceeds
Reiterates 2008 guidance of revenues of $162-$169MM and diluted EPS of $.92-$.98
GAINESVILLE, Fla. -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has entered into definitive agreements with certain institutional investors to sell 877,391 shares of its common stock at a price of $23.00 per share, resulting in gross proceeds of approximately $20.2 million and net proceeds of approximately $18.8 million after offering expenses and placement agency fees. Exactech offered the shares pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The offering is expected to close on or before May 14, 2008 and is subject to certain closing conditions.
Exactech Q1 Revenue Increases 34% to $39.8 Million
Net Income up 49% to $2.8 million and EPS of $0.23
GAINESVILLE, Fla. – April 29th, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $39.8 million for the first quarter of 2008, an increase of 34% compared to $29.6 million for the first quarter of 2007. Net income for the quarter was $2.8 million, or $0.23 per diluted share, a gain of 49% from the $1.9 million, or $0.16 per diluted share, in the same quarter a year ago. First quarter diluted earnings per share included a gain of $0.03 due to a forward currency call option and a loss of $0.01 per share due toExactech’s minority investment in Altiva prior to the acquisition.
